ResearcherSpanish National Cancer Research CentreActive in the last 2 years
Spas Dimitrov Markov
Matched on ORCID iD 0000-0002-1297-5986; OpenAlex author ID A5085246414. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 23
2020: 2 papers · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 4
- Systemic immunosuppression limits NK cell therapy efficacy in pancreatic cancer. Co-author DOI 10.1186/s12943-025-02340-8↗
- IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-21-0368↗
- Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia. First author DOI 10.1016/j.canlet.2020.04.017↗
- Discovery of New Targets to Control Metastasis in Pancreatic Cancer by Single-cell Transcriptomics Analysis of Circulating Tumor Cells. Co-author DOI 10.1158/1535-7163.mct-19-1166↗
Closest collaborators
The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kamiya Mehla · 3 shared papers, 2020–2026 · strength 0.42
- Paper Systemic immunosuppression limits NK cell therapy efficacy in pancreatic cancer. DOI 10.1186/s12943-025-02340-8↗
- Paper Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia. DOI 10.1016/j.canlet.2020.04.017↗
- Paper IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer. DOI 10.1158/1535-7163.mct-21-0368↗
- Michael Anthony Hollingsworth · 3 shared papers, 2020–2026 · strength 0.42
- Paper Systemic immunosuppression limits NK cell therapy efficacy in pancreatic cancer. DOI 10.1186/s12943-025-02340-8↗
- Paper Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia. DOI 10.1016/j.canlet.2020.04.017↗
- Paper IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer. DOI 10.1158/1535-7163.mct-21-0368↗
- Surendra Kumar Shukla · 3 shared papers, 2020–2026 · strength 0.42
- Paper Systemic immunosuppression limits NK cell therapy efficacy in pancreatic cancer. DOI 10.1186/s12943-025-02340-8↗
- Paper Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia. DOI 10.1016/j.canlet.2020.04.017↗
- Paper IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer. DOI 10.1158/1535-7163.mct-21-0368↗
- Ryan J. King · 2 shared papers, 2020–2026 · strength 0.33
- Tuo Hu · 1 shared paper, 2026 · strength 0.22
- Chunbo He · 1 shared paper, 2026 · strength 0.22
- Sai Sundeep Kollala · 1 shared paper, 2026 · strength 0.22
- Ravi Kumar Thakur · 1 shared paper, 2026 · strength 0.22
- Marina Pasca di Magliano · 1 shared paper, 2026 · strength 0.22
- Howard C. Crawford · 1 shared paper, 2026 · strength 0.22
- Pankaj Kumar Singh · 2 shared papers, 2020–2021 · strength 0.20
- Paul M. Grandgenett · 2 shared papers, 2020–2021 · strength 0.20
- Aneesha Dasgupta · 1 shared paper, 2020 · strength 0.11
- Enza Vernucci · 1 shared paper, 2020 · strength 0.11
- Kuldeep Singh Attri · 1 shared paper, 2020 · strength 0.11
- Thomas C. Caffrey · 1 shared paper, 2021 · strength 0.10
- Ryan L. Hanson · 1 shared paper, 2021 · strength 0.10
- Elizabeth M. Jaffee · 1 shared paper, 2021 · strength 0.10
- Prakash Radhakrishnan · 1 shared paper, 2021 · strength 0.10
- Ling Huang · 1 shared paper, 2020 · strength 0.09
- Manuel M. Hidalgo · 1 shared paper, 2020 · strength 0.09
- Bruno Bockorny · 1 shared paper, 2020 · strength 0.09
- Senthil K. Muthuswamy · 1 shared paper, 2020 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.